At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 86 enrolled
Drug / intervention
LY2140023 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Placebo- and Positive-Controlled Study of the Electrophysiological Effects on the QT Interval After a Supratherapeutic Dose of LY2140023 in Subjects With Schizophrenia
In Brief
A Phase 1 clinical trial evaluating LY2140023, Placebo, and 1 other intervention for Schizophrenic Disorders. Completed, enrolled 86 participants across 8 sites.
Detailed Summary
This study determined if a single dose of LY2140023 (pomaglumetad methionil) affects the electrical activity in the heart in participants with schizophrenia. This study also helped determine how a single high dose of LY2140023 is tolerated by participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenic Disorders
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMay 2012
Enrollment StartJun 2012
Primary CompletionAug 2012
Study CompletionSep 2012
TodayJul 2026
First PostedMay 25, 2012
Enrollment StartJun 1, 2012
Primary CompletionAug 1, 2012
Study CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 14.1 years ago
Interventions
LY2140023drug
Administered orally.
Placebodrug
Administered orally.
Moxifloxacindrug
Administered orally.